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ABSTRACT  
Background 
Cryptococcal meningitis (CM) remains an ongoing and devastating disease with 
detrimental outcomes accounting for up to 44% of acquired immune deficiency 
syndrome (AIDS) related mortality. A significant portion of the cases have been 
attributed to recurrences, thought to be largely preventable. In the first world the 
recurrence rate is estimated at <5% but it is more than double that rate in developing 
countries. In the era of freely available antiretroviral therapy (ART) and secondary 
prophylaxis with fluconazole, we endeavoured to study the prevalence along with the 
clinical and laboratory features of patients with recurrence of CM in our setting. 
 
 
Objectives 
1. Determine the prevalence of recurrent CM at Chris Hani Baragwanath Academic 
Hospital (CHBAH) for patients with the incident presentation between the years 
2012-2013. 
2. Determine the use of ART and fluconazole in patients with recurrent CM.   
The patients were divided into 4 groups reliant on whether they were on ART and 
fluconazole at the time of diagnosis of recurrent CM. 
a. Patients on ART and fluconazole. 
b. Patients on ART alone. 
c. Patients on fluconazole alone. 
d. Patients on no therapy. 
3. Describe the clinical and laboratory features of patients with recurrent CM, as a 
cohort and by group. The groups were comparatively analysed. The variables studied 
included clinical presentation, mortality and cerebrospinal fluid (CSF) findings.  
 
 
Methods  
This was a retrospective review of adult patients presenting to Chris Hani 
Baragwanath Academic Hospital (CHBAH) with recurrent CM. The patients were 
identified using the Group for Enteric, Respiratory, and Meningeal disease 
Surveillance for South Africa (GERMS-SA) database. This is a nationwide network of 
clinical microbiology laboratories (both in the public and private sector) participating 
in an active laboratory-based surveillance programme for bacterial and fungal 
pathogens of public health importance. Specimen of patients identified to have CM are 
submitted to the National Institute of Communicable Diseases for confirmation and 
further characterisation.  CHBAH is one of 25 enhanced surveillance sites where 
additional data including demographics, clinical findings and laboratory results were 
recorded. Hospital records and laboratory results were used to supplement the data. 
Patients with recurrent CM were identified between February 2012 and April 2014. 
The incident episode of CM had to have been from January 2012 to December 2013. 
The number of incident cases in that period was the denominator for the rate of 
recurrence. 
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Results 
A total of 51 patients were identified from the database from an incident cohort of 658 
patients with CM giving a prevalence rate for recurrent CM of 7.8%. These 51 patients 
had a total of 62 recurrent episodes of CM. Eight (15.7%) patients had multiple 
recurrences. There were 30 (58.8%) males and the median CD4 count was 85/mm3 
(IQR: 3-393/mm3). The median time to recurrence was 143 days (IQR: 32-633 days). 
 
Data on the use of ART and fluconazole was available for 56 (90.3%) of recurrent 
episodes in 45 patients. A total of 37 (66.1%) recurrent episodes were in patients on 
ART and 26 (46.4%) were on fluconazole. The 56 episodes of recurrent CM were 
grouped as follows: 
1. A total of 20 (35.7%) recurrent episodes were in patients on both ART and 
fluconazole. Immune reconstitution syndrome (IRIS) contributed 14 cases. 
2.  A total of 17 (30.4%) of recurrent episodes were in patients only on ART. 
3. A total of 6 (10.7%) of the recurrent episodes were in patients on fluconazole 
prophylaxis only.  
4.  A total of 13 (23.2%) of the recurrent episodes were in patients on no therapy. 
The patients presented clinically with headaches (76.8%), meningism (57.1%), a 
Glasgow Coma Scale (GCS) <15 (30.4%) and seizures (14.3%). Twenty-seven (48.2%) 
cases died in hospital. Mortality was significantly higher in those with a GCS of less 
than 15 (82% vs. 33%, P=0.0008) and those with seizures (86% vs. 42%, P=0.0197). 
No statistically significant differences were noted amongst the 4 groups with respect 
to the clinical presentation, cerebrospinal fluid profile, the time to recurrence and 
mortality.  
 
Conclusion 
The prevalence of recurrent CM was midway between that of the developed world and 
a pre-ART study in Gauteng. Recurrent CM had a high mortality. The finding that one-
third of patients were not on ART and that more than half were not on fluconazole at 
the time of diagnosis of recurrent CM, together with the high rate of multiple 
recurrence requires further investigation. Explicit steps need to be taken to link 
patients with health care facilities to ensure reliable provision of fluconazole and the 
initiation of ART. 
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CHAPTER 1: LITERATURE REVIEW 
  
1.1 Introduction 
Cryptococcal meningitis (CM) is a common opportunistic infection in immune-
compromised patients particularly those with human immunodeficiency virus 
infection/acquired immune deficiency syndrome [HIV/AIDS]. It remains amongst the 
leading causes of mortality in HIV particularly in Southern Africa despite the advent 
of antiretroviral therapy (ART). It accounts for up to 13%-44% of HIV associated 
mortalities [1]. The estimated current global burden of CM amongst individuals with 
HIV/AIDS ranges from 0.04%-12% per year, highest in developing countries [2]. 
There are about 500 000 deaths attributed to CM each year in sub-Saharan Africa 
with a case fatality of between 35%-65% as compared to 10%-20 % in developed 
countries [3]. 
 
1.2 Background 
Cryptococcus neoformans is the causative organism, an encapsulated fungus, 
ubiquitous and largely benign in health. In immunocompromised states such as AIDS, 
inhalation leads to haematological spread and dissemination to multiple organs with 
particular predilection for the central nervous system. The initial primary pulmonary 
infection is often asymptomatic and manifestations of the disease depend on the host 
immune response. The organism is either eliminated or contained and in vulnerable 
individuals may present with asymptomatic cryptococcal antigenemia or invasive 
symptomatic mycoses manifesting as sub-acute or chronic meningitis, less commonly 
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as space-occupying intracranial lesions and at other foci including the liver, lungs and 
skin.   
 
1.3 Diagnosis 
The diagnosis of CM is on the basis of cerebrospinal fluid (CSF) analysis. The 
organism may be identified by india ink stain in 74%-88% of cases. Fungal culture is 
the gold standard with theoretically 100% cases of CM being culture positive. CSF 
cryptococcal antigen detection by latex agglutination is rapid and reliable in the 
diagnosis of CM, being positive in 99% of CM; it offers 93%-98% diagnostic 
sensitivity and specificity in the region of 93%-99% [4]. 
 
1.4 Treatment 
The World Health Organization (WHO) recommends induction therapy with 
amphotericin B deoxycholate at 0.7-1mg per kilogram of body weight per day for 14 
days in conjunction with flucytosine at 100mg/kg where available, followed by 
consolidation with fluconazole at doses of 400-800 mg for 8 weeks then subsequently 
at 200 mg daily as secondary prophylaxis until the CD4+ T-cell (CD4) count is 
maintained above 200 cells/mm³ for a period of more than 6 months [3]. 
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1.5. Recurring crypotococcal meningitis 
1.5.1 Disease burden in our environment 
Cryptococcal meningitis still poses a major challenge especially in the developing 
world despite the availability of both subsidized fluconazole by Pfizer since 2000 and 
freely available ART [5]. Along with other variables that will be discussed, socio 
economic difficulties, modest access to equipped health facilities and difficulties with 
patients presenting late with advanced cryptococcal disease still pose a challenge in 
curbing the disease and its complications. 
 
In the population of Soweto, a study conducted in 1996 examining the spectrum of 
meningitis encountered over a year showed CM to account for 13% of all cases, with 
the leading cause being tuberculous meningitis (TBM): 25.4% followed by acute 
bacterial meningitis: 22.5%, viral meningitis: 14.1% with the trend expected to 
increase particularly for TBM and CM given the increasing rate of HIV at the time (6) 
In 2009, in sub-Saharan Africa there were an estimated 720000 cases of CM yearly 
with cryptococcosis contributing to 504 000 deaths compared to 347 871 due to 
tuberculosis [2].  
Screening for serum cryptococcal antigen (CRAG) in patients prior to ART with a 
median CD4 of 97/mm3 (IQR 46-157cells/ mm3) has shed light into the prevalence of 
asymptomatic cryptococcal antigenemia, thus allowing for great strides to be taken in 
the decrease of CM and associated mortality.  
The incidence of a positive serum CRAG which was 100% sensitive for predicting 
developing CM within the first year was found to be 7 percent [7]. 
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Recurring CM still constitutes a sizeable quantity of the cases of CM to date, 
remaining fairly common even with more efforts directed at HIV/AIDS; in the 
developed world contributing approximately 5% of the cases seen [8]. In Gauteng, 
recurrences of CM were recognized to have an estimated incidence of 9.5% between 
2002-2004 in a population-based surveillance in ART naïve patients [9]. 
 
Multiple variables have been described which may contribute to relapses. In our 
resource-limited environment where flucytosine is unavailable, amphotericin B is 
primarily used either alone or in combination with fluconazole in the induction 
phase, perhaps contributing to a number of relapses thought to be due to persistence 
of the infection from inadequate fungal CSF clearance. Multiple cohort studies have 
repeatedly shown that combination therapy with amphotericin B and flucytosine in 
the induction period increases CSF sterilization and significantly reduces relapses 
and mortality [10]. A recent randomized, three group open label trial comparing 
induction therapy with amphotericin B alone, in combination with flucytosine or with 
fluconazole in 299 patients showed significant reduction in mortality in the group 
who received flucytosine in addition to amphotericin B, (with 15 vs. 25 deaths at day 
14     (P: 0.08) and 30 vs. 44 deaths at 70 days (P: 0.04).  
There was no superiority in sterilizing the CSF, nor a survival benefit demonstrated in 
the group that received dual fluconazole and amphotericin B compared to the group 
on amphotericin B monotherapy [10]. 
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Poor compliance or suboptimal drug dosing with fluconazole have also been shown to 
contribute significantly to relapses. A prospective study conducted at GF Jooste 
hospital in Cape Town (a public sector hospital which has been a site for numerous 
studies in CM) showed that as many as 43% of the 69 cases of CM relapses were due 
to inadequate secondary prophylaxis i.e. patients not taking fluconazole for various 
reasons [11]. 
 
There are concerns of emerging and growing resistance towards fluconazole, with 76 
percent of the cases of culture positive CM being associated with isolates showing 
reduced susceptibility to fluconazole in a study from Cape Town [1]. This high rate of 
resistance has not been replicated in other studies.  
 
Decreased efficacy of fluconazole with concurrent use of rifampicin has been 
proposed; It is thought that rifampicin may decrease the serological concentration of 
fluconazole and hence the efficacy when taken concurrently. 
 
Immune reconstitution inflammatory syndrome (IRIS) is a well-recognised and 
perhaps a very common complication of ART initiation and accounts for a significant 
number of cases of CM recurrences. 
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1.5.2. Immune reconstitution inflammatory syndrome (IRIS) 
IRIS has in recent years become a topic of much interest and research.  The entity is 
grouped into unmasking [CM] and paradoxical IRIS [12]. The definitions used in this 
article are based on criteria published elsewhere. See Annexure C 
Concisely, unmasking IRIS encompasses a new recognition of cryptococcal disease 
occurring after the introduction of effective ART. Paradoxical IRIS is worsening of a 
recognized disease, which previously showed symptomatic improvement. Evidence of 
immune reconstitution (most reliably a decline in viral load) is important in the 
diagnosis and equally so, the exclusion of other conditions and infections which may 
mimic the process.  Refer to Annexure C for detailed proposed case definitions.    
The CSF will mostly be culture negative if occurring after 3 months, with a decrease in 
the cryptococcal titer, the authors quoted have defined a significant decline to be 4 
fold from the initial cryptococcal antigen titer [12]. 
 
Cryptococcal IRIS is fairly common and has been described in as many as 8-50 
percent of individuals initiating ART [13]. The pathophysiology of IRIS continues to 
elude researchers, particularly due the heterogeneity of the patients with CM 
developing IRIS after commencing ART. IRIS is thought to occur from defective 
antigen clearance by the immune system from the preceding episode of CM, a high 
CRAG at initiation of ART as well as during the episode being both risk factors. When 
recovery of pathogen specific T cell immunity ensues, an aberrant inflammatory 
response occurs, demonstrated by high-designated T helper 1 type cytokines.  
 7 
Other theories such as a dysregulation in immunity between the effector and 
suppressor cells have been disproven [14].  
 
In an American study conducted in Texas examining CM IRIS in an HIV seropositive 
population, the incidence was 30% in the cohort of 84 patients. The patients at risk 
for IRIS were ART naïve with a high CSF CRAG supporting the hypothesis mentioned 
earlier [15]. 
 
Work conducted in Uganda examining the mortality of CM before ART and after the 
ART era found the figures to be comparable primarily due to the development of IRIS 
in the latter group. In the study IRIS was reported in 7 of the 24 patients after 
commencing ART, with 5 patients presenting with aseptic meningitis [16].   
 
Another prospective study conducted in South Africa with 65 patients initiating ART 
revealed 17% of the individuals developed CM IRIS at a median time of 29 days [17]. 
The reported time of onset of IRIS varies widely and occurs from as early as 4 days up 
to 3 years, the median time is 1 to 10 months with individuals bearing a CD4 of 
50/mm3 or less being at a particularly increased risk. Other recognized risk factors 
include a high viral load prior to ART initiation and early initiation of ART i.e. 
commencement of ART earlier than 5 weeks after the episode of CM [12]. The risk of 
IRIS seems to increase with profound immune deficiency and appears to be lower if 
switched from a failing ART regimen.  
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A high fungal burden as evidenced by an elevated CRAG is also associated with IRIS. 
Other factors include a paucity of initial CSF inflammation, which also seems to have a 
strong association with IRIS [14]. 
 
The diagnosis of IRIS can be challenging. Shelburne et al. reported patients with IRIS 
to show higher mean opening pressures and white blood cell counts as opposed to 
individuals with HIV associated CM; of the 84 patients followed up over 1.48 years, 17 
patients developed culture negative meningitis (3 unmasking and 14 paradoxical 
IRIS). [15] They also found the risk factors for developing IRIS to be a higher viral 
load pre-ART initiation along with a higher CSF CRAG (1:4096 vs 1:1024 p=0.020) 
and early ART commencement at less than 30 days (RR 1.73; CI 1.03-2.29; P=0.031). 
Patients who developed IRIS presented earlier as opposed to those presenting with 
relapse of CM (59 days vs 165 days; P=0.29) with higher intracranial pressures 
documented in the IRIS group (45 vs 31cm H20 P=0.38). [15] 
 
There are no conclusive tests for a definitive diagnosis of IRIS, and the diagnosis is 
generally made once relapses due to therapy failure and other causes are excluded.  
The factors that favour the diagnosis include evidence of CSF inflammation with a 
higher CSF white cell count, decreasing CSF CRAG and a decrease in the HIV viral load. 
The test shown to be more sensitive is a negative CSF culture; this may delay the 
diagnosis as the turnaround time for the result can be weeks with a low CSF fungal 
load [18].   
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1.5.3. Inadequate secondary prophylaxis 
There is a rising regularity of poor adherence to secondary prophylaxis. Some of the 
encountered challenges are poor patient education, socioeconomic difficulties leading 
to patients being lost to follow up and failure to be retained within facilities that will 
ensure continued adherence.  Sub-therapeutic doses of fluconazole may contribute to 
relapse of disease especially important in the maintenance/suppressive phase of 
therapy. 
A prospective observational study referenced previously at GF Jooste Hospital in Cape 
Town indicated the commonest cause for relapses to be patients not taking their 
fluconazole prophylaxis, this number constituting 43% of the total number in the 
study. The in-hospital mortality was also high in this group (33%). They found that 
47% of the individuals did not have fluconazole prescribed by health care providers 
[11]. 
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1.5.4. Antifungal resistance 
There are fears regarding the emergence of resistance to current antifungal therapy 
Bicanic et al. suggested that there may be an emergence of resistant isolates of 
cryptococcus neoformans [1]. This is plausible concern especially given the free use of 
fluconazole for CM as well as other fungal infections. 
Pfaller et al. at the University of Iowa conducted a surveillance of cryptococcal 
isolates from 5 different global sites including Africa/ Europe/Latin America /Pacific 
and North America, in the surveillance conducted between the years 1990-2004, a 
total of 1811 clinical isolates of cryptococcus neoformans were tested against 
commonly used antifungals including amphotericin B, fluconazole and flucytosine. 
98-100% of isolates were susceptible to amphotericin B irrespective of geographic 
region with minimal inhibitory concentrations (MIC) less or equal to 1mcg/ml. 
Isolates from North America were 75% susceptible to fluconazole (MIC< or equal to 
8mg/ml) as compared to the rest of the regions  where 94-100 % showed 
susceptibility.  Susceptibility to flucytosine ranged from 35% to 68% in North 
America and Latin America respectively. Five sites from Africa were involved in the 
study, 395 isolates contributed to the total number mentioned. There was 99% 
susceptibility to amphotericin B at an MIC of 1mcg/ml. 97 % of isolates were 
susceptible at an MIC of 8mcg/ml for both fluconazole and flucytosine [19]. 
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1.5.5 Drug interactions 
Concomitant therapy that the patient may be on may have significant drug-drug / 
pharmacokinetic interactions, which could considerably lower drug concentrations 
for fluconazole particularly in the CSF. This may have significant implications for 
further recurrences. Rifampicin is a potent inducer of the hepatic cytochrome p450 
oxidative enzyme, and a number of drugs including fluconazole are affected. A Thai 
study revealed that co-administration of rifampicin with fluconazole caused 
significant changes in the pharmacokinetic parameters of fluconazole. They 
demonstrated a 39% increase in the elimination rate constant, a 28% shorter 
elimination half time, 17 % decrease in the maximum concentration and 30% 
increase in clearance of fluconazole (p<0.05). [20]  
This is in line with a paper by Coker et al (1990) who reported clinical relapse in 3 
case studies in patients on concurrent fluconazole and rifampicin, [21] with another 
study revealing fluconazole to be less effective in decreasing candida colony counts in 
4 individual on anti-tuberculosis therapy [22]. This raises questions about the 
possible need to adjust the fluconazole dose for patients receiving tuberculosis 
therapy. 
Jarutanasirikul et al. conversely reported no clinically significant effect of fluconazole 
on rifampicin; they postulated that this might be due to a low inhibitory affinity of 
fluconazole to mammalian cytochrome p450 systems and the metabolic pathways of 
rifampicin not being primarily independent on the activity of cytochrome p450 [23]. 
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1.5.6. Suboptimal therapy at initial episode of cryptococcal meningitis 
The gold standard for the treatment of CM involves an intensive phase of high dose 
amphotericin B at 0.7mg/kg-1mg/kg daily along with flucytosine at 100mg/kg for a 
period of 2 weeks. This regimen has repeatedly been shown to be superior in 
sterilizing the CSF [3]. 
 
In a randomized 3 group trial, combination therapy with flucytosine and 
amphotericin B showed better organism clearance from the CSF (-0.42 log10 colony 
forming units (CFU) per milliliter per day vs 0.31 and 0.32 log10 CFU per milliliter 
per day in the groups receiving monotherapy with amphotericin B and amphotericin 
B with fluconazole respectively( P<0.001). [10]Further support from work by Van 
Der Horst et al. showed that combination therapy with flucytosine and amphotericin 
B was associated with marked CSF sterility [24], along with a study by Saag et al. 
demonstrating that the best predictor of relapse was the lack of flucytosine in the 
initial 2 weeks of therapy [25]. There appears to be synergy between amphotericin B 
and flucytosine therapy supporting the data that it is the most fungicidal regimen 
available [26]. 
 
In a study comparing the fungicidal activity of various antifungal drug combinations, 
64 patients presenting with an index episode of CM were randomly assigned to 
groups.  They were randomized to receive the following treatment: amphotericin B; 
amphotericin B with fluconazole; amphotericin B with flucytosine and amphotericin 
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B/fluconazole/ flucytosine triple therapy, with the endpoint being the reduction in 
CFU at day 3,7,14 of treatment. Clearance was faster in the amphotericin B and 
flucytosine group than in the amphotericin B (p:0.0006) , amphotericin B plus 
fluconazole (p: 0.02)  or triple therapy group (p:0.02). [27]  
 
In 1993, Spitzer et al. proposed inadequate clearance of the initial CM to be the major 
factor in recurrent disease. Pulsed field electrophoresis of intact chromosomes and 
southern blot hybridization with two genomic DNA probes were utilized to 
investigate the genetic relation between the initial case of CM and the subsequent 
episode. Four patients were studied and the strains were differentiated using 
electrophoretic karyotyping using three independent methods. Results showed the 
initial and recurrent isolates of cryptococcus neoformans to be clonally related and 
thus corroborated the notion of recurrence of the initial strain in recurrent disease, 
This data suggests that inadequate cryptococcus neoformans clearance may be a 
contributor to relapses [28]. 
 
Other contributions may be the use of fluconazole monotherapy. Amphotericin B 
deoxycholate is a drug with a significant side effect profile; It is not uncommon due to 
drug related toxicities for therapy to be interrupted and at times completely stopped 
leaving only fluconazole, a fungistatic agent as the backbone for therapy.  
The benefit of a repeat lumbar puncture at the end of therapy to ensure CSF sterility 
is uncertain and is not standard practice in most institutions. Whether ensuring CSF 
sterility at discharge may decrease relapses in the future is unclear.  
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1.5.7 Immunodeficiency  
Ongoing profound immunodeficiency translating to impaired CSF immunity plays a 
major role in disease eradication and recurrences.  It is not unusual for patients to be 
lost to follow up, often presenting with persistent immunodeficient states with 
recurring disease. In a study conducted in Cape Town at GF Jooste hospital looking at 
relapses of CM, 8% of the 69 patients studied relapsed pre-ART while on fluconazole 
[1]. 
Increased fungal burden at the time of presentation associated with delayed 
presentations to health care facilities is an important consideration, and may 
predispose to future relapses from suboptimal fungal clearance. There are studies 
that also suggest a link between the initial high CRAG titers and immunodeficiency to 
the subsequent development of IRIS [11]. 
 
Ample work has taken place in trying to determine the optimal time for ART initiation 
after an incident of CM, most studies seem to concur with delayed ART initiation in 
improving survival and the incidence of IRIS. 
 Commencement of ART at 5 weeks or later from the date of the initial CM episode is 
recommended as earlier initiation is associated with significant mortality. There is a 
mortality risk of 45% vs 30% in the group where ART was commenced before 2 
weeks. The same study showed no statistically significant benefits in the secondary 
outcome (i.e. IRIS and relapses) occurring in similar numbers in both groups: 8/88 in 
the group with ART at 5 weeks and 2/89 in the group with ART at 1-2 weeks (p: 
0.06). [29] 
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2.0. Study objectives  
 1.  Determine the prevalence of recurrent CM for the period under analysis at Chris 
Hani Baragwanath Academic Hospital [CHBAH].  
2.  Determine the profile of the patients who presented with recurrences of CM. 
To aid in this, the patients are divided into 4 groups. The groups were based on the 
presence of ART and /or fluconazole therapy at the time of diagnosis. 
The groups were as follows: 
2.1. Patients on ART and fluconazole 
This group included patients with IRIS. 
2.2. Patients on ART alone 
2.3. Patients on fluconazole alone 
2.4. Patients on no ART or fluconazole/no therapy 
3. To describe the clinical and laboratory features and outcome of patients with recurrent 
CM, as a cohort and by group. The variables compared included the time to relapse, 
the clinical presentation, CSF profiles and mortality.   
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Chapter 2: Materials and Methods 
2.1. Methodology  
This was a retrospective descriptive study of patients with recurrent CM. 
Patients were identified using the Group for Enteric, Respiratory, and Meningeal 
disease surveillance for South Africa (GERMS-SA) database. A nationwide network of 
clinical microbiology laboratories (both in the public and private sector) participating 
in an active laboratory-based surveillance programme for bacterial and fungal 
pathogens of public health importance. Approximately 200 South African clinical 
laboratories participate in the surveillance programme. Clinical isolates and specimen 
are submitted to the National Institute for Communicable Diseases (NICD) for 
confirmation and further characterisation. CHBAH is one of 25 enhanced surveillance 
sites were additional data is recorded. The additional information is recorded on a 
case report form and entered onto the database. Hospital and laboratory records 
were used to supplement the data.  
Patients with recurrent CM between February 2012 and April 2014 were identified. The 
incident episode of CM had to have been from January 2012 to December 2013. The 
number of incident cases in that period was the denominator for the rate of recurrence. 
 
 
2.2. Site of study: 
CHBAH, Soweto, South Africa is a 2700-bed public sector university hospital serving 
the population of Soweto. 
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2.3. Inclusion criteria  
1. All adult patients (≥18 years of age) admitted to CHBAH medical wards with 
recurrent CM between February 2012 and April 2014 where another cause of the 
clinical presentation was excluded. 
2. Patients needed to have documented evidence of previous (CSF positive) CM >30 
days preceding the admission, the first episode occurring during the period of 
01/01/2012-31/12/2013. 
3. The denominator in calculating the prevalence was the total number of cases of 
incident CM at CHBAH between 01/01/2012-31/12/2013. 
 
The patients were grouped as follows: 
 
A. Patients on ART and fluconazole: this included patients with IRIS and relapse.  
B. Patients on ART alone and not on fluconazole: these patients were considered 
to have a relapse. 
 
C. Patients on fluconazole 
 
D.  Patients on no treatment 
 
Please refer to annexure A: flow diagram on study objectives  
 
 
 
 
 
 
 
 
 18 
2.4. Data Analysis 
STATA 12.0 software program was used for data analysis with the aid of a statistician. 
Baseline characteristics for each group were summarized as means and standard 
deviations or medians with interquartile ranges for continuous data depending on 
normality of the data. For categorical data, proportions or percentages were used. 
Box plots and other graphical measures were utilized to describe the data, and tests 
for normality were performed. For categorical data, proportions between the groups 
were compared using the Chi squared test if the expected value was above 5, and 
Fisher exact if less than 5. Means and medians for the continuous variables between 
the groups were compared using the student T test and Wilcoxon sum rank 
respectively depending on normality. A P value of less than 0.05 was considered as 
significant for the analysis. 
 
2.5. Ethics 
Approval from GERMS-SA to use the database was obtained. Since there was patient 
anonymity, no consent from the patients was required. For the denominator, only   
the number of patients was obtained. For patients with recurrent CM, patients were 
assigned a study number and the patient names and folder numbers were kept 
separately on a master sheet to protect confidentiality. A letter from CHBAH for 
permission to perform the study was obtained. The proposed study was approved by 
the University of Witwatersrand Human Research Ethics Committee. See Annexure D 
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Chapter 3: Results  
3.1. The prevalence of cryptococcal meningitis recurrence 
There were 658 incident cases of CM between the 1st of January 2012 and the 31st of 
December 2013. There were 51 patients identified with recurrences of CM who had a 
total of 62 episodes of recurrence.  The prevalence of CM recurrence in our setting 
was thus 51/658, calculated at 7.8%. Amongst the 51 patients, there were 43 patients 
with 1 recurrence (84.3%), and 8 patients with multiple recurrences (15.7%). 
(Amongst the 8 patients with multiple recurrences; 1 patient had 4 recurrences, 1 
patient had 3 recurrences, and 6 patients had 2 recurrences). 
3.2. Profile of patients 
All patients were HIV seropositive with AIDS by definition. Within the 51 patients, 
there were 30 (58.8%) males and 21 (41.2%) females.  The mean age was 37.5 years 
(IQR: 24-54 years). 
 
Taking into account that a number of patients had multiple recurrences, I have 
elected to describe the various episodes of recurrences and cluster these into the 
groups dependent on the use of ART and fluconazole. 
In 51 patients with 62 episodes of recurrences, 51(82.3%) episodes was the first 
recurrence of CM and 11 (17.7%) episodes of recurrence were in patients who had 
had at least 1 previous recurrence of CM and are therefore placed in a category of 
≥2nd recurrence of CM. 
 
Figure 1: Profile of episodes of recurrent CM  
 20 
 
FLUC: fluconazole 
ART: Antiretroviral therapy 
 
Data on the use of ART and fluconazole was available for 56 out of the 62 episodes of 
recurrent CM in 45 patients. These 56 episodes of recurrent CM are further studied in 
the sections that follow, and are referred to as episodes of recurrence 
 
 
3.3. Profile of recurrent episodes of CM 
 
Episodes of recurrent CM in patients on ART contributed a total of 66.1% and 33.9% 
of the episodes were in patients not on ART. 
 
The Group distributions of the 56 recurrent episodes of CM. 
 
A. Twenty (35.7%) of the recurrent episodes were in patients on ART and 
fluconazole. 
B. Seventeen (30.4%) of the recurrent episode were in patients on ART alone. 
 
 
C. Six (10.7%) of the recurrent episodes were in patients on fluconazole alone. 
 
D. Thirteen (23.2%) episodes of recurrences were in patients on no therapy. 
 
 
0
2
4
6
8
10
12
14
16
ART/FlUC ART/No FLUC FLUC/NO ART NO ART/NO
FLUC
1st recurrence
≥2nd recurrence
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The biggest group of 20 episodes of recurrent CM was in patients on both ART and 
fluconazole. IRIS was diagnosed in 14 of these patients, which was 25% of the whole 
cohort and 70% of this group. These 14 cases of IRIS had recurrent symptomatic CM 
with negative CSF fungal cultures without evidence of ART failure, that is a recovering 
CD4 count and a decreasing viral load based on the proposed criteria. See Annexure C. 
Those patients who were still had a positive CSF fungal culture beyond 3 months 
from the initial episode of CM were not considered to have IRIS. It must be noted that 
some cases called IRIS may still have been from relapses from treatment failure. 
There were 5 deaths amongst the 14 patients with IRIS. 
 
3.4.The clinical presentation  
 
Table 1: The clinical presentation of the groups 
 
Group N Headache  Meningism GCS <15 Seizures Died 
ART/FLUC 20 15 (75.0%)   7 (35.0%) 5 (25.0%) 3 (15.0%) 9 (45%) 
ART/NO 
FLUC 
17 14 (82.4%) 12 (70.6%) 4 (23.5%) 2 (11.8%) 
 
9 (52.9%) 
FLUC/NO 
ART 
 6   4 (66.67%)   3 (50%) 4 (66.7%) 0 4 (66.7%) 
NO 
ART/NO 
FLUC 
13 10 (76.9%) 10 (76.92%) 4 (30.8%) 3 (23.1%) 
 
5 (38.5%) 
TOTAL 56 43 (76.8%) 32 (57.1%) 17 (30.4%)  
 
8 (14.3%) 27 (48.2%) 
GCS: Glasgow Coma Scale  
ART: Antiretroviral therapy 
FLUC: fluconazole 
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Table 2: CSF findings, CD4 count and time to recurrence 
Characteristic Total(N) Median(interquartile 
range) 
CD4 count: index episode( mm3) 
CD4 count: recurrent episode mm3 
 
 
Lymphocytes/mm3   
Neutrophils/mm3 
Erythrocytes/mm3 
Protein g/l 
Glucose mmol/l 
 
Time to recurrence ( days) 
 
24 
52 
CSF  
 
54 
54 
54 
51 
51 
 
55 
 
 
 
 
 
52 (0-182) 
85 (3-393) 
 
 
42 (0-385) 
8    (0-121) 
14  (0-360) 
1.19 (0.29-8.3) 
1.7    (0.2-3.9) 
 
142 (32-633) 
 
 
 
Figure 2: Patients on ART: viral loads 
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37 patients were on ART, 27 had viral loads results and only 12 were virally 
suppressed. 
 
Figure 3: The clinical presentations by groups dependent on ART/fluconazole 
 
 
Headache and meningism were the commonest presenting features occurring in 76.8 
% and 57.1% of the cases respectively. A decline in GCS occurred in less than a third 
of the cases.  The occurrence of seizures seemed to be evenly distributed amongst the 
groups, occurring in all groups apart from the group on fluconazole only. 
Meningism was less reported in patients on fluconazole with or without ART, 10/26 
(38.5%) compared to those not on fluconazole, 22/30 (73.3%), p=0.018. There were 
no other significant differences in the manner of presentation among the various 
groups. 
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3.5. Mortality rates 
 
The total in-hospital mortality rate for CM recurrences was 48.2% (27/56 died). 
The patients with seizures had a significantly increased in-hospital mortality rate of 
85.7 % (7/8died) as compared to 41.7% (20/48) without seizures; p=0.0197. 
Patients with decline in level of consciousness as measured by the Glasgow Coma 
Scale (GCS) also demonstrated an increased in-hospital mortality rate of 82.4 % 
(14/17 died) as compared to the mortality in individuals with a normal GCS  of 33% 
(13/39died); p=0.0008.  There were 5 (35.7%) deaths in the 14 IRIS patients. 
 
FIGURE 4 Mortality rates 
 
 
 
The mortality of 48.2%: group distribution  
3.6. A comparison between the incident and recurrent CM episodes.   
45 (80.4%) of the 56 cases with recurrent CM had   CSF results from both the index 
episode and the recurrent episode, which enabled comparison.  
The results are shown on the table that follows:  
0
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ART/FLUC
:16.1%
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FLUC:16.1%
NO
ART/FLUC:7%
NO ART/NO
FLUC:9%
 number of patients
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Table 3: CSF comparison of incident and recurrent episode of CM. 
  
ART/FLUCONAZOLE 
ART, NO 
FLUCONAZOLE 
NO ART,ON 
FLUCONAZOLE 
NO ART AND 
NO 
FLUCONAZOLE 
TOTAL P-value 
 
n= 15 13 7 10 45  
GENDER Male n (%) 8 (53.3) 10 (76.9) 3 (42.9) 9 (90.0) 30 (66.7) 
0.109 
 
Female n (%) 7 (46.7) 3 (23.1) 4 (57.1) 1 (10.0) 15 (33.3) 
AGE (years) 
 
37±7 37±7 45±7 38±5 38±7 0.047 
CLINICAL PRESENTATION- No (%)  
 n= 13 13 7 10 43  
HEADACHES 
Yes n (%) 12 (92.3) 10(76.9) 6 (85.7) 9 (90.0) 37 (86.0) 
0.692 
No n (%) 1 (7.7) 3 (23.1) 1 (14.3) 1 (10.0) 6 (14.0) 
SEIZURES 
Yes n (%) 3(20)  2(15.4) - 3(30)  8(17.78) 
 
      
GCS 
Normal 10 (66.7) 9 (69.2) 3 (42.9) 7 (77.8) 29 (65.9) 
0.515 
Abnormal <15 5 (33.3) 4 (30.8) 4 (57.1) 2 (22.2) 15 (34.1) 
CSF findings  
 n= 15 13 7 10 45  
CSF ON FIRST 
PRESENTATION 
Lymphocytes /mm3 60±94 11±18. 143±159 159±241 102±192 0.317 
Neutrophils /mm3 0±1.5 9±20 3.8±8 28±61 10±31 0.192 
Erythrocytes /mm3 3±10 1±3 60±159 39±82 20±75 0.257 
Protein g/l 1.11±0.66 0.93±0.46 1.22±0.61 1.23±0.42 1.1±0.52 0.544 
Glucose mmol/l 1.91±0.78 2.06±0.62 1.63±0.68 1.11±0.7 1.73±0.78 0.020 
Culture (Positive) 12 (92.3) 11 (100.0) 7 (100.0) 10 (100.0) 43 (97.7) 
0.577 
Culture (Negative) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.3) 
CRAG titre 1888±938 2234±618 1765±750 1869±567 1963±707 0.513 
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  ART/FLUCONAZOLE ART, NO 
FLUCONAZOLE 
NO ART,ON 
FLUCONAZOLE 
NO ART AND 
NO 
FLUCONAZOLE 
TOTAL P-value 
 n= 15 13 7 10 45  
CSF ON 
SECOND 
PRESENTATION 
Lymphocytes  /mm3 40±40 54±110 28±31 63±101 65±148 0.761 
Neutrophils /mm3 8±23 19±36 2±4 19±57 12±34 0.634 
Erythrocytes /mm3 0±2 5±14 8±14 49±102 15±51 0.129 
Protein g/l 1.09±0.69 1.03±0.57 0.74±0.23 0.91±0.2 0.99±0.49 0.374 
Glucose mmol/l 1.71±1.17 1.99±0.85 2.31±0.98 1.11±0.72 1.71±0.99 0.081 
Culture (Positive) 8 (66.7) 9 (81.8) 2 (28.6) 7 (87.5) 27 (65.9) 0.091 
Culture(Negative) 4 (33.3) 2 (18.1) 3 (42.8) 1 (12.5) 14 (34.1)  
CRAG titre 1274 1834 658 1754 1380 
0.587 CD4 count 
/mm3  
134±103 69±69 92±48 42±21 89 ± 78 
OUTCOME n (%) ALIVE 5 (38.5) 7 (63.6) 2 (28.6) 8 (80.0) 24 (54.5) 
0.175 
 
DIED 8 (61.5) 4 (36.4) 5 (71.4) 2 (20.0) 20 (45.5) 
TIME TO 
RELAPSE days 
± SD 
 
127±57 122±67 141±161 115±50 132±93 0.701 
 
 
 
The variables were compared to elicit any differences between the first and second CSF.  No statistically significant difference was 
found in any parameter. 
The clinical parameters in the 45 cases used here were similar to those in the total group and therefore suggest that they were 
representative of the total group. 
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Chapter 4: DISCUSSION 
 The study was descriptive aimed at defining the prevalence of recurrent CM and 
describing the clinical, laboratory profiles and outcomes of recurrent CM in the age of 
freely available ART and secondary prophylaxis in the population of Soweto, Gauteng, 
South Africa. The prevalence of cryptococcal meningitis recurrences in our 
population was 7.8%. The figure was lower than the 9.5% reported in a surveillance 
study in patients pre-ART conducted in Gauteng in 2002-2004, but was higher than 
the 5% reported in the developed world [8,9]. The prevalence of recurrent CM 
remains high, however it must be kept in mind that the CM IRIS contributed 25% to 
the cohort. IRIS/ART related recurrences of CM would not have contributed to the 
pre-ART sample in 2002-2004. 
 
Among the 56 recurrent episodes of CM scrutinized, a total of 66% were on ART and 
only 46% were on fluconazole. This was an indirect measure of the efficacy of the 
health system and reflects suboptimal rates of ART initiation and fluconazole 
treatment and secondary prophylaxis in patients who had experienced a serious 
opportunistic infection.  
The biggest group of patients (35.7%) were documented to be on both ART and 
fluconazole. IRIS accounted for recurrent CM in a majority (70%) of this group and 
for 25 % of all CM recurrences.  It is challenging to accurately define the incidence of 
IRIS in most clinical settings.  It is largely a diagnosis of exclusion as there are no 
definitive markers for a diagnosis and mostly becomes a presumptive inference based 
on patterns.  These include a negative CSF fungal culture, a fall in CRAG titre, and a 
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decrease in HIV viral load [12,17].  Not all, if any, of these laboratory tests are 
available in many areas of sub-Saharan Africa where the majority of patients with CM 
are situated. An additional challenge is the criteria for IRIS in the various studies are 
generally not uniform, and largely dependent on resources [12]. 
 
The 25% of IRIS cases in this study is midway between the incidences reported both 
locally and internationally. Data out of Cape Town by Bicanic et al. showed IRIS to 
occur in 17% of their sample population. (11 of the 65 patients in this 2009 
prospective study). Interestingly another earlier study conducted in the same centre 
in 2007/2008 by Jarvis et al. showed IRIS to contribute to 45% of the relapses [11, 
17]. It must be noted that in the two studies the patients commenced ART at different 
times, which may have accounted for the higher rates in the one study. A Thai study 
by Sungkanuparph et al. showed an incidence of 13%, 13 patients with IRIS were 
identified out of a cohort of 101 patients [12]. A higher prevalence in Uganda was 
reported as seen in a prospective cohort by Kambugu et al, with 42 cases in this study 
of 85 demonstrating features of probable IRIS. The incidence was calculated at 42 
[12,16]. The lowest incidence was documented in a french study with an incidence of 
8% reported [12].  
 
The second commonest group accounting for 30% of the relapses was fluconazole 
interruption in those taking ART.  Cases not on fluconazole irrespective of ART 
contributed 54% of the cohort. This supports other studies showing failure to 
continue secondary prophylaxis contributed significantly to cases of relapse.   
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In a prospective Cape Town study, there were 69 relapse episodes accounting for 
23% of all cases of cryptococcal meningitis.  43% (n: 30) of these relapse episodes 
were in patients not taking fluconazole prophylaxis and of the 30 patients not taking 
fluconazole 47% (n: 14) had not been prescribed secondary prophylaxis by their 
healthcare providers [11]. In our study the reasons for fluconazole interruption were 
not available.  In many cases, it likely reflected failures in the health system. In some 
cases, fluconazole could have been stopped by a doctor or nurse if a patient on ART 
with a suppressed viral load had a CD4 count >200/mm3.  
 
The smallest group of 10.7% was in cases on fluconazole without ART. Fluconazole 
used as secondary prophylaxis has been shown to prevent relapse of CM [3]. The 
group on no therapy (23.2% of cases) may have represented a group with no follow-
up or loss-to-follow up following the incident episode of CM.  
 
The overall median time to relapse was 142±115 days in the 56 episodes of 
recurrence, but with a wide range of one month up to almost 2 years. The longest 
median time to relapse was in the group on fluconazole at 141 days. The shortest 
time was in the group on no therapy (115 days). The groups on ART and fluconazole 
relapsed at 127 days, this may be explained by the cases of probable IRIS occurring 
earlier than relapses, commonly within 1- 10 months as described in the literature 
[13].There was a male predominance with a total of 58.8% patients (male-to-female 
ratio of 1.4:1). This was higher than the 49% described in a previous surveillance 
study in South Africa [9]. Whether this points to males being at an increased risk of 
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relapses is uncertain, we did not have the gender distribution of the incident patients. 
The clinical presentation did not differ amongst the groups. The most common signs 
and symptoms were headache, meningism, a decreased level of consciousness and 
seizures in order of decreasing frequency. It is noteworthy that headache and 
meningism did not occur in all patients, which can make diagnosis of CM difficult. 
The signs and symptoms of cases with recurrent CM were no different to those seen 
in other cases of CM. A local study reported headache to be the commonest symptom 
(79%) followed by meningism (67%), fever, altered GCS (32%) with seizures only 
contributing 4% [30].  
There was no significant difference in the CSF profiles between the groups. The CSF 
parameters of recurrent CM changed slightly relative to the initial episode.  There 
was a higher CSF protein, lower glucose level, and a higher CSF neutrophil cell count 
as compared to the initial episode in patients on ART and fluconazole; but the 
difference was not statistically significant. A high CSF white blood cell count has been 
reported as a common occurrence in IRIS cases [17,18]. 
 
The findings of lower CSF culture rates and CRAG titers may be explained by the cases 
of IRIS. Interestingly there were CSF culture negative recurrences in the group on 
fluconazole and no ART. The reason may have been a low fungal burden in the 
presence of fluconazole.  The laboratory may have discarded cultures before they 
could become positive, as culture may be delayed up to a month before becoming 
positive [31]. 
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The overall mortality for recurrent CM was 48.2%.   In the sub-group of patients 
taking fluconazole without ART, 4 out of the 6 demised. Due to the small numbers the 
significance of this high mortality is uncertain.  There was significantly increased 
mortality in patients with seizures and a low GCS, these features occurred evenly 
amongst the groups. The mortality was 85, 7% and 82, 5% respectively in patients 
with seizures and a low GCS. The mortality rate of CM described in the literature 
ranges between 13-44%, largely influenced by the availability of resources. [3]. The 
in-hospital mortality rate found in this study of recurrent CM is at the higher end. 
This is higher than the mortality rate in sub-Saharan Africa of 30%.  Higher rates 
were reported in Uganda in the pre- ART era, with 42 % in-hospital mortality 
improving in the HAART era to 20% at 14 days [16]. In a prospective IRIS study in 
Cape Town, the reported mortality in IRIS was 36% (4 patients out of 11), which is 
similar to that in the current study [17]. The mortality rate for IRIS in this study was 
35.7%. The reason for such the increase in the mortality rate in this study is likely 
multifactorial. The mortality rate is largely influenced by the availability of resources 
in institutions, along with timeous presentation to healthcare facilities. The mortality 
rates are much lower in developed resource rich environments, especially with the 
use of flucytosine together with amphotericin B for induction therapy [3]. 
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Chapter 5: Limitations 
This was a retrospective study and as such some information may have been missing 
or not documented correctly. This lack of accurate data may have been exacerbated 
by the fact that almost a third of patients had a documented reduced GCS. 
 
The prevalence rate may have been affected by a number of possible factors. For the 
numerator, some patients with recurrent CM may have died in the community or 
sought medical attention at other hospitals; so the numerator for prevalence may 
have been falsely reduced.  Similarly some of those discharged after the incident 
episode of CM may have died without recurrence and the denominator for prevalence 
may have been falsely elevated. We were not able to obtain adequate records for 11 
(20%) episodes of recurrent CM. Because some patients had more than one episode 
of recurrence, this led to confusion between patients and episodes, so we have used 
the terms cases or episodes for these recurrences. 
Since resistance testing is not routine and repeat lumbar punctures to determine 
sterility of CSF were not usually performed, we were not able to comment on 
resistance or possible organism persistence from CSF on the initial presentation  
We accepted GERMS-SA data and diagnosis as CM when rehospitalised. There was no 
detailed information on fluconazole prescription or its use prior to hospitalization in 
the database and some of the bed letters, thus it was difficult to be certain of the 
compliance on fluconazole prior to hospitalization using GERMS-SA records and bed 
letters. IRIS still carries challenges with regards to a confident diagnosis.  
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There may be differences in clinical and laboratory features of patients with 
recurrent CM but the numbers were too small to show these. Bigger numbers of 
patients may be required to further elucidate the significance of a number of the 
variables.   
 
 
Chapter 6: Conclusion  
The prevalence of CM recurrence was 7.8%, which was midway between the 
developed world rate and the pre-ART Gauteng study rate [8,9].  More than 1 in 6 
episodes of recurrence were in patients with a history of a previous recurrence of CM.   
  
 Two-thirds of the cases were documented to be on ART, while almost half were on 
fluconazole. This means that one-third of the cases had not yet started ART and more 
than half were not receiving fluconazole. The reason for this together with the high 
rate of multiple recurrences requires further investigation. The largest group in the 
cohort was on both ART and fluconazole but this was still merely 35.7%, while 11% 
were on no therapy. IRIS was common and contributed 25 % to the recurrent cases.  
There was no significant difference in the clinical features or CSF findings between 
groups. The in-hospital mortality of cases was 48.2%, and was significantly more 
common in those who had a low GCS or who had seizures.  
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The management of patients with CM remains a challenge. This includes management 
of the hospitalized patient as well as education of the patient and family members as 
to the nature of his or her illness and the need for lifelong treatment. It also requires 
explicit steps to link the patient with a clinic or hospital to ensure the reliable 
provision of fluconazole and the initiation of ART.  
 
Recommendations for future work 
The possible impact of TB and its treatment on recurrences of CM needs to be 
examined. This would involve measuring fluconazole levels in patients receiving 
rifampicin to investigate whether fluconazole levels become subtherapeutic. 
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ANNEXURE A 
 
 
 
  
 
 
 
 
All recurrent 
cases of CM n:62
occuring after 30 
days after 
diagnosis n:56
a. patients on 
ART 37
b. patients not on 
ART n:19
occurring after 
30 days but could 
not be grouped 
n:6
a. on ART n:37
+fluconazole n:20
no fluconazole n:17
b. not on ART 
n:19
+ fluconazole 
n:6
no fluconazole 
n:13
 39 
 
ANEXURE B      
 
                                         DATA SHEET 
 
Study Number 
 
Age: 
 
Gender: 
 
HIV:        Y/N 
Fluconazole: Y/N 
DOSE: 
DURATION: 
BACTRIM: Y/N 
 
ART:       Y / N 
 
IF Yes: Duration 
             : Regimen 
 
CD4       AT ADMISSION: 
                Baseline: 
 
 VL:          At admission 
                  At Baseline 
OTHER COMRBIDITIES: 
 
PREV EPISODES OF CM: 1-6M 
                                                6-12M 
                                                 >1 YEAR 
 
SYMPTOMS AND SIGNS 
 
Headache:   Y/ N 
 
Decline in GCS:  Y/N 
FOCAL SIGNS Y/N 
If yes list: 
 
 L N E PROT GLUC CL I. INK CRAG CULTURE 
EPISODE1           
EPISODE2          
EPISODE3          
EPISODE4          
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 WCC HB MCV PLT NA K CL UR CR 
ADMISSION 
1 
         
2          
3          
4          
 
 
 
 
Discharged:   Y/N 
 
Died:      Y/N 
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ANEXURE C 
 
IRIS DEFENITIONS BASED ON THE INTERNATIONAL NETWORK FOR THE 
STUDY OF HIV ASSOCIATED IRIS(INSHI) 
 
 
 
Panel 1: Case definition for paradoxical cryptococcal immune reconstitution 
inflammatory syndrome in patients HIV-1 
Antecedent requirements 
• Taking antiretroviral therapy 
• Cryptococcal disease diagnosed before ART by positive culture or typical clinical 
features plus positive India ink staining or antigen detection 
• Initial clinical response to antifungal therapy with partial or complete resolution of 
symptoms or signs, fever, or other lesions, or reduction in CSF cryptococcal antigen 
concentration or quantitative culture 
Clinical criteria 
• Event occurs within 12 months of ART initiation, reintroduction, or regimen switching 
after previous failure 
• Clinical disease worsening with one of the following inflammatory manifestations of 
cryptococcosis (see text for possible rarer manifestations): 
• Meningitis 
• Lymphadenopathy 
• Intracranial space-occupying lesion or lesions 
• Multifocal disease 
• Cutaneous or soft-tissue lesions 
• Pneumonitis or pulmonary nodules 
Other explanations for clinical deterioration to be excluded 
• Non-adherence or suboptimum antifungal therapy, indicated by an increase in 
quantitative culture or antigen titre, or any positive cryptococcal culture after 
3 months of antifungal therapy 
• Alternative infection or malignant disease in the affected site 
• Failure of ART excluded if possible (eg, failure to achieve ≥1 log10 copies/mL decrease in 
viral load by 8 weeks of ART) 
ART=antiretroviral therapy. CSF=cerebrospinal fluid 
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Panel 2: Proposed case definitions for antiretroviral-therapy-associated cryptococcosis 
and unmasking cryptococcal immune reconstitution inflammatory syndrome 
ART-associated cryptococcosis 
• Patient taking ART 
• No recognised cryptococcal disease at ART initiation 
• Clinical disease worsening caused by cryptococcosis occurs after initiation, 
re-introduction, or regimen switch after previous failure (supported by 
microbiological, histological, or serological evidence) 
• Cryptococcal infection characterised by meningitis, CNS complications, skin or 
soft-tissue lesions, lymphadenopathy, lung disease, or disseminated disease 
Unmasking cryptococcal IRIS (provisional) 
• Criteria for ART-associated cryptococcosis are met 
• Unusual, exaggerated, or heightened inflammatory manifestations, such as the 
following: 
• Meningitis with CSF WBC >50Å~10⁶ /L or CSF opening pressure >20 cm that is 
refractory to therapy 
• Painful or suppurating lymphadenopathy 
• Rapidly expanding CNS lesions, cryptococcomas 
• Unusual focal site (ie, not within the CNS, lung, skin, or lymph nodes) 
• Granulomatous inflammation on histology 
• Pneumonitis, particularly if cavitating or necrotic 
• Event occurs early after ART initiation* 
• Failure of ART excluded if possible (eg, ≥1.0 log10 copies/mL decrease in HIV-1 viral 
load by 8 weeks treatment) 
ART=antiretroviral therapy. IRIS=immune reconstitution infl ammatory syndrome. 
CSF=cerebrospinal fluid. WBC=white blood 
cell count. *No specific time limit is proposed for unmasking cryptococcal IRIS, pending further 
research. Typically, onset within 
3 months of starting ART could be assumed to support a diagnosis of IRIS owing to early and rapid 
changes in immune function. 
However, late presentations of cryptococcal IRIS have been reported in patients with good 
responses to therapy assessed 
by CD4 cell counts. 
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ANEXURE D 
 
